martien kas
play

Martien Kas From diagnose to biology ISCTM ~ ECNP Joint Conference - PowerPoint PPT Presentation

Jan 29, 2023 •460 likes •944 views

Preclinical models of negative symptoms and their implications for clinical trials Martien Kas From diagnose to biology ISCTM ~ ECNP Joint Conference 1 September 2017 Paris France The road to restoring neuronal circuits Canter et

  1. Preclinical models of negative symptoms and their implications for clinical trials Martien Kas

  2. From diagnose to biology ISCTM ~ ECNP Joint Conference ▪ 1 September 2017 ▪ Paris ▪ France

  3. The road to restoring neuronal circuits… Canter et al., Nature, 2016

  4. The puzzle of schizophrenia stahlonline.cambridge.org

  5. Integrated experimental approaches Dolmetsch and Geschwind, Cell, 2011

  6. How to provide cross-species clinically relevant and quantitative endpoint measures?

  7. Behavioural domains across the neuropsychiatric spectrum Kas et al., Molecular Psychiatry, 2007

  8. Behavioural domains: negative symptoms Modeling positive versus negative symptoms in animals

  9. Social withdrawal is a common (early) symptom across neuropsychiatric disorders Schizophrenia Autism Spectrum Disorder Social withdrawal Alzheimer’s Disease Bipolar Depression Major Depression

  10. Social withdrawal is influenced by several processes Social learning Cognitive performance Social perception Social withdrawal Reward processing Social information processing Emotionality Mentalizing activities

  11. Social withdrawal is influenced by several processes Social learning Cognitive performance Social perception Social withdrawal Reward processing Social information processing Emotionality Mentalizing activities

  12. The dopamine hypothesis Brunelin et al., 2013

  14. Rodent models to alter dopamine signalling • Striatal D 2 R overexpression mouse model • Amphetamine model • Dopamine transporter knock-out mice • Neonatal ventral hippocampal lesion • Isolation rearing

  15. Recombinant technologies to delete or overexpress the Dopamine-2 receptor in mice Drew et al. J. Neuroscience, 2007

  16. Reward processing: testing motivation

  17. Performance in the progressive ratio task Drew et al. J. Neuroscience, 2007

  18. Evolutionary conserved biological processes?

  19. Social withdrawal is influenced by several processes Social learning Cognitive performance Social perception Social withdrawal Reward processing Social information processing Emotionality Mentalizing activities

  20. Social information processing

  21. Social recognition 70 60 50 duration (s) 40 30 20 10 0 5 minutes 24 hours

  22. Mapping a locus on mouse chromosome 14 for long-term social recognition Mapping a locus on mouse chromosome 14 for social recognition Bruining et al., Biological Psychiatry, 2015

  23. Pcdh9: associated to social behavioural deficits in human and dogs

  24. Pcdh9 -deficient mice: impaired social recognition Bruining et al. Biol. Psychiatry, 2015

  25. Sensory processing deficits in Pcdh9 KO mice Touch evoked biting response Sensorimotor performance Prepulse inhibition

  26. Cortical thinning of sensory cortex, and local dendritic and spine malformations Bruining et al., Biological Psychiatry, 2015

  27. Mouse and human Sensory information processing Cortical integrity Genetic variations

  28. From genetic variation to behavioural output Temporal & Synaptic density Spatial

  29. Coupling sensory processing to neural biomarkers integrated EEG – behavioural analyses

  30. Sensory deficits: auditory mismatch negativity

  31. Disease diversity

  32. Precision medicine Insel and Cuthbert, Science, 2015

  33. PRISM: Psychiatric Ratings using Intermediate Stratified Markers Project coordinator: Martien Kas, University of Groningen, the Netherlands Project leader: Hugh Marston, Eli Lilly and Company, United Kingdom The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  34. PRISM’s general concept: “ Providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in Alzheimer’s disease, schizophrenia and depression” The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  35. 23 partners, including major EU Academic Centres, SME’s and pharmaceutical industry The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  36. Human and rodent homologies The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  38. Longitudinal and objective measures of rodent and human social withdrawal The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  39. BeHapp – passive remote behavioural monitoring The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  40. Collected Data – smartphone app MMS messages GPS location SMS messages Bluetooth signals in the area Outgoing calls WiFi signals Returned calls Incoming calls Application activity, such as: Missed calls Twitter events The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  41. Smartphone passive behavioural monitoring Movement trajectory extraction The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  42. Longitudinal and objective measures of rodent and human social withdrawal The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  43. Mimicking natural burrowing behaviour The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  44. Visible Burrow System: studying social interaction in a semi-natural environment The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  45. BTBR: Reduced social interaction and huddling The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  46. Summary • Improving treatment efficacy in schizophrenia will benefit from advancing our knowledge on target neural circuitries and representative core readout. • Understanding clinical heterogeneity requires the development and application of quantitative biological parameters that can be applied across the diagnostic boundaries. • Implementation of homologous clinical and preclinical testing paradigms to assess quantitative biological parameters allow for the development of preclinical model systems to back-translate human findings and further expand our neurobiological knowledge. The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

  47. VIDI-grant The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

More recommend